Ferrières J, et al. - Whether or not body mass index (BMI) influences the choice of lipid lowering treatment was investigated in a large, real world cohort of 52,916 patients treated with statins. This cross-sectional, observational, multicenter study [The Dyslipidemia International Study (DYSIS)] in statin-treated patients≥45 years of age from 30 countries demonstrated a correlation of BMI with high-density lipoprotein cholesterol (HDL-C) and triglycerides but not with low-density lipoprotein cholesterol. An increase in statin intensity in association with increasing BMI was noted. This association remained consistent after adjustment for comorbidities on BMI ≥30 kg/m² for atorvastatin equivalent ≥40mg/day.